Here are the best performing FTSE 250 stocks in 2022 so far!

Andrew Woods looks at the reasons why these three FTSE 250 stocks have seen their share prices surging since the beginning of the year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young brown woman delighted with what she sees on her screen

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I often trawl through the FTSE 250 in the hope of finding the best growth stocks to add to my portfolio. Although they’re not the biggest companies on the market, the shares can occasionally provide exciting growth opportunities. Let’s take a look at the best performers from the index in 2022.

For the year to date, Euromoney Institutional Investors (LSE:ERM), Mediclinic International (LSE:MDC), and QinetiQ (LSE:QQ) lead the way in share price performance. While the way the shares move is obviously important, I want to delve deeper to understand what the driving forces are behind these moves.

StockPerformance (year to date)Performance (1 year)
Euromoney Institutional Investors42.05%29.77%
Mediclinic International41.45%58.86%
QinetiQ40.83%7.35%

Euromoney

Euromoney was subject to a takeover offer from a couple of private equity firms and the current offer on the table is equivalent to 1,461p per share. At the time of writing, the shares are trading at 1,314p.

The private equity companies seem keen to complete the takeover of Euromoney, a financial publishing firm, given that they’ve made four previous offers.

For the six months to 31 March, the company reported that revenue had increased by 14% year on year. Furthermore, adjusted pre-tax profit grew by 16% to £38.6m over the same time period. 

However, it’s still unclear how the economic environment and the war in Ukraine may impact the business, and whether these factors will lead to a fall in demand for services, which means this is a risk.  

Mediclinic

Like Euromoney, Mediclinic has also been subject to an offer from a consortium. The approach, worth somewhere in the region of £3.4bn, was rejected last month. Despite this, the takeover deadline has been extended, meaning that talks are still under way.

The shares are currently trading at 474p.

For the year ended March — which included some months when the effects of the pandemic were still visible — operating profit at the business surged 34% to £280m and revenue was above pre-pandemic levels. Of course, these figures make sense, given that there were likely increased levels of client demand during the pandemic.

However, with the worst of the Covid crisis behind us, it’s possible that results will not be as impressive in the future.

QinetiQ

Finally, the QinetiQ share price has performed well this year. The company – a defence specialist – has a strong forward order book to supply governments around the world with weapons and equipment.

Indeed, there has been heightened interest from investors due to the ongoing war in Ukraine and the shares are currently trading at 380p. 

The business had a net cash balance of £225m at the end of March, while it estimates that it will derive £900m in revenue from contracts due in 2023. 

However, while the company is in a healthy financial position, much of the share price performance of late has come from the fallout from the war in Ukraine. That conflict won’t last forever, and I wonder if an end to hostilities might result in the shares falling.

Overall, these three firms top the index for share price performance in 2022. But while they’re all attractive propositions, there are too many unknowns for my liking. Yet I won’t rule out purchases in the future, when things are a bit clearer.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andrew Woods has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 no-brainer buys for my Stocks and Shares ISA in 2025

Harvey Jones picks out a couple of thriving FTSE 100 companies that he's keen to add to his Stocks and…

Read more »

Number three written on white chat bubble on blue background
Investing For Beginners

3 investing mistakes to avoid when buying UK shares for 2025

Jon Smith flags up several points for investors to note when it comes to thinking about which UK shares to…

Read more »

Investing Articles

Will the rocketing Scottish Mortgage share price crash back to earth in 2025?

The recent surge in the Scottish Mortgage share price caught Harvey Jones by surprise. He was on the brink of…

Read more »

Investing Articles

2 cheap shares I’ll consider buying for my ISA in 2025

Harvey Jones will be on the hunt for cheap shares for his ISA in 2025 and these two unsung FTSE…

Read more »

Investing Articles

I am backing the Glencore share price — at a 3-year low — to bounce back in 2025

The Glencore share price has been falling for some time, but Andrew Mackie argues demand for metals will reverse that…

Read more »

Road trip. Father and son travelling together by car
Investing Articles

A 10% dividend yield? There could be significant potential here to earn a second income

Mark Hartley delves into the finances and performance of one of the top-earning dividend stocks in his second income portfolio.

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Charlie Munger recommended shares in this growth company back in 2022. Here’s what’s happened since

One of Charlie Munger’s key insights is that a high P/E ratio shouldn’t put investors off buying shares if the…

Read more »

Investing Articles

What might 2025 have in store for the Aviva share price? Let’s ask the experts

After a rocky five years, the Aviva share price has inched up in 2024. And City forecasters reckon we could…

Read more »